Drug Profile
Clavulanic acid - Ocuphire Phrama
Alternative Names: Clavulanic acid CR - Ocuphire Pharma; Clavulanic acid extended-release (Serdaxin) - Ocuphire Pharma; Clavulanic acid IR - Ocuphire Pharma; RX-10100; Serdaxin; ZoraxelLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Revaax Pharmaceuticals
- Developer National Institute of Neurological Disorders and Stroke; Rexahn Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antidepressants; Anxiolytics; Azetidines; Carboxylic acids; Erectile dysfunction therapies; Neuroprotectants; Oxazolidinones; Small molecules
- Mechanism of Action Beta lactamase inhibitors; Dopamine release stimulants; Serotonin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Erectile dysfunction; Major depressive disorder
Highest Development Phases
- Discontinued Anxiety disorders; Erectile dysfunction; Major depressive disorder; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 05 Nov 2020 Rexahn Pharmaceuticals has been merged with Ocuphire Pharma to form Ocuphire Pharma
- 27 Jun 2014 Clavulanic acid - Rexahn is available for licensing as of 21 Mar 2014. http://www.rexahn.com/cms/
- 21 Mar 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)